Selank vs Davunetide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Selanc, TP-7
Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from the natural immune peptide tuftsin, with a small chemical tweak to make it last longer in the body. It was developed in Russia as an anti-anxiety and nootropic agent and is approved there for generalized anxiety disorder, but it has no FDA or EMA approval and almost no Western clinical data. The pitch is calm and focus without the sedation, dependence, or withdrawal that come with benzodiazepines.
Also: NAP, AL-108
Davunetide (NAP) is an eight-amino-acid fragment (NAPVSIPQ) of activity-dependent neuroprotective protein (ADNP), discovered at Tel Aviv University and given as a nasal spray. It was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. Its big test, a phase 2/3 trial in progressive supranuclear palsy (PSP), failed cleanly in 2012, and development stalled. It has since been revived by its inventors, who argue it works in women and are pursuing ADNP syndrome, but those claims rest on reanalyses of old data, not a new successful trial.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Selank | Davunetide |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Selank seems to work through several overlapping systems rather than one tidy target. It influences GABA signaling, the brain's main calming neurotransmitter system, which likely accounts for its anti-anxiety effect. It also slows the breakdown of enkephalins, the body's own opioid-like peptides involved in mood and stress, which is a mechanism entirely different from benzodiazepines or SSRIs. Animal work additionally points to effects on serotonin and dopamine balance and on BDNF, a growth factor tied to learning and neuron health. These pathways are well documented in rodents; the picture in humans is inferred rather than directly measured. | NAP comes from ADNP, a protein essential for brain development. In cell and animal studies it interacts with microtubule end-binding proteins (EB1 and EB3), promoting microtubule stability and reducing tau phosphorylation, which is why it was aimed at tauopathies like PSP and Alzheimer's disease. Mutations in the ADNP gene itself cause ADNP syndrome (Helsmoortel-Van der Aa syndrome), and in ADNP-deficient mice NAP improved some behavioral and neural measures, the rationale for that newer program. The PSP trial did not include target-engagement measures, so it never showed the drug was actually doing this in human brains. |
| Common Dosing | 250-500 mcg 2-3x daily 2-3x daily | 30 mg intranasal twice daily (PSP trial dose) Once or twice daily |
| Administration | Intranasal spray (most common), subcutaneous injection | Intranasal spray (an IV form, AL-208, was tested in cardiac surgery) |
| Typical Duration | 14-21 days typical | 12 weeks to 52 weeks in trials |
| Best Time to Take | Morning or as needed for anxiety | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Most of the rigorous data is preclinical and Russian. In rodents, Selank shows consistent anxiety-reducing and mild cognitive effects, and one PMC-indexed study found it enhanced diazepam's anti-anxiety effect under chronic stress. The main human clinical reference is a Russian comparative trial by Zozulia, Neznamov, and colleagues in patients with generalized anxiety disorder and neurasthenia, reporting that Selank's anxiolytic effect was comparable to the benzodiazepine medazepam on standard rating scales, with added anti-fatigue benefits and changes in enkephalin activity. The honest caveat: that trial was relatively small, the published English abstract gives qualitative results rather than hard effect sizes and p-values, and it has not been replicated by independent Western groups. So the evidence supports a real but modestly studied anxiolytic, mostly validated within the regulatory system that approved it. | The headline result is negative. In the phase 2/3 PSP trial (Boxer and colleagues, Lancet Neurology 2014), 313 patients got 30 mg intranasal davunetide twice daily or placebo for 52 weeks. Disease progression was identical in both groups on both primary measures (PSP Rating Scale and Schwab and England daily living scale), and the authors concluded davunetide is not an effective treatment for PSP. Earlier phase 2 work was mixed: a 12-week trial in 144 people with amnestic mild cognitive impairment hinted at working-memory benefits, and a schizophrenia trial missed one co-primary endpoint while hitting another. The original developer, Allon Therapeutics, stopped investing and was later absorbed by Paladin Labs. The revival comes from the inventor's group: post hoc reanalyses of the PSP data (Translational Psychiatry 2023, Molecular Psychiatry 2026) report that women declined faster than men and that davunetide slowed decline in women only. A similar sex-split reanalysis of the MCI trial was published in 2024. These findings are interesting but are subgroup analyses of trials that failed overall, done by researchers tied to the company now developing the drug (ExoNavis Therapeutics), so they need a new prospective trial to mean much. ExoNavis has said a phase 3 in children with ADNP syndrome began in 2024, but Alzforum could not find it in trial registries. Davunetide holds FDA orphan and rare pediatric disease designations and EMA orphan status for ADNP syndrome. |
Frequently Asked Questions: Selank vs Davunetide
What is the difference between Selank and Davunetide?
Selank is a cognitive peptide that selank is a synthetic seven-amino-acid peptide (thr-lys-pro-arg-pro-gly-pro) built from the natural immune peptide tuftsin, with a small chemical tweak to make it last longer in the body. it was developed in russia as an anti-anxiety and nootropic agent and is approved there for generalized anxiety disorder, but it has no fda or ema approval and almost no western clinical data. the pitch is calm and focus without the sedation, dependence, or withdrawal that come with benzodiazepines. Davunetide is a cognitive peptide that davunetide (nap) is an eight-amino-acid fragment (napvsipq) of activity-dependent neuroprotective protein (adnp), discovered at tel aviv university and given as a nasal spray. it was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. its big test, a phase 2/3 trial in progressive supranuclear palsy (psp), failed cleanly in 2012, and development stalled. it has since been revived by its inventors, who argue it works in women and are pursuing adnp syndrome, but those claims rest on reanalyses of old data, not a new successful trial. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Selank or Davunetide?
Neither is universally "better" - the choice depends on your specific goals. Selank is typically used for cognitive purposes, while Davunetide is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Selank and Davunetide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Selank and Davunetide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.